Introduction
Cumulative, excessive estrogen exposure from both endogenous and exogenous sources can lead to pathological consequences in multiple human tumors, including breast cancer (Crooke et al., 2011) . Experiments have shown that estrogen is an important regulator of growth and differentiation in the normal mammary gland and is important in the development and progression of breast carcinoma (Medina et al., 2001) . Epidemiological evidence has provided support for the association between estrogen levels and breast cancer in postmenopausal women (Russo et al., 1998; Key et al., 2002) . In vivo, the biological actions of estrogen are mediated by estrogen receptors (ESRs), which interact with other cell-signaling pathways to influence cell behavior. There are two major types of ESRs, including ESR-α and ESR-β. In breast cells, the ESR-α plays an important role in regulating cell proliferation and differentiation through a paracrine mechanism (Mallepell et al., 2006) . Mammary glands from the ESR-α knockout mouse do not undergo ductal Disrupted ESR-α signaling may result in reduced estrogen-responsive gene products in the mammary gland (Bocchinfuso et al., 2000) . A recent study by Liu et al. found that ESR-α plays an important role in regulating p53 activity. ESR-α binding to p53 leading to functional inactivity of wild-type p53 could be one reason for the inability of wild-type p53 to inhibit tumor growth and metastasis in ESR-positive breast cancer (Liu et al., 2006) . Thus, genetic variations in genes controlling estrogen activity, including ESR-α, could reveal a potential risk for breast cancer. The rs2234693 (PvuII, C/T) and rs9340799 (XbaI, G/A) polymorphisms of the ESR-α gene are most commonly reported as associated with breast cancer. In 1992, the first report to evaluate these associations was published by Yaich and his colleagues (Yaich et al., 1992) . They identified a random subset of 257 cases of primary breast cancer and 140 controls without breast cancer in the United States. Based on their analysis, the PvuII polymorphism was not associated with estrogen receptor content or patient age at tumor diagnosis. Although this conclusion was also supported by Wedrén et al. in Sweden (Wedren et al., 2004) , other researchers, such as Cai et al. (2003) and Onland-Moret et al. (2005) , have failed to show this same result with different populations. Another polymorphic variant XbaI did not show any association with breast cancer risk in a Shanghai (China) population (Cai et al., 2003; Shen et al., 2006) , but it was strongly correlated with susceptibility to breast cancer in Korean women (Shin et al., 2003) . The inconsistent association outcomes are probably due to differences in the study populations. In the present study, we have carried out a case-control study to investigate the relationship between the PvuII and XbaI polymorphisms of ESR-α gene and breast cancer risk in the Chinese population, as one salient characteristic of China's population that it possesses a large base of diverse genetic backgrounds. The present study can provide a platform to help explain the pathological mechanism of breast cancer and a better understanding of the geographic and ethnic differences associated with disease incidence and mortality.
Since it can be difficult for individual studies to achieve sufficient statistical power to detect associations between the ESR-α gene polymorphisms and breast cancer risk, a meta-analysis that combines data from all published studies may detect genetic associations more accurately. In addition, a reduced probability of false-negatives might also be achieved (Egger et al., 2003) . Therefore, a systematic meta-analysis of population-based studies was performed to investigate the association between the ESR-α polymorphisms and breast cancer risk.
Materials and Methods

Study population in our study
Between March 2007 and October 2010, a total of 542 female breast cancer patients with a mean age of diagnosis of 50.60 years (range 25-83 years) were enrolled in the study from the Zhejiang region in China. All cases diagnosed were confirmed by pathological examination. In addition, 1,016 unrelated healthy women with a mean age of 48.64 years (range 18-84 years) were recruited as controls. The controls were screened to ensure that there had never been a diagnosis of cancer. All subjects were informed about the contents of the study and gave their informed consent. This study was approved by the Ethics Committee of Wenzhou Medical University, Wenzhou, China.
Genotyping and quality control
Blood samples were collected with the anticoagulant EDTA K2 and stored at -20°C. Genomic DNA was isolated using a DNA Extraction Kit (TaKaRa Bio Group, Japan) and stored at -20°C. ESR-α genotypes were determined by a PCR-RFLP method reported earlier (Kobayashi et al., 1996) . The specific primers for analysis were 5'-CTG CCA CCC TAT CTG TAT CTT TTC CTA TTC TCC-3' (forward) and 5'-TCT TTC TCT GCC ACC CTG GCG TCG ATT ATC TGA-3' (reverse). For the positive internal control, the primer 5'-TCC ACC ACC CTG TTG CTG TA-3' (forward) and 5'-ACC ACA GTC CAT GCC ATC AC-3' (reverse) coding for human GAPDH gene was used. The negative control utilized the same reagents as those used with actual samples, but without the DNA templates. In addition, a total of 155 samples (about 10%) were randomly selected and genotyped and confirmed by DNA sequencing by a second investigator.
Meta-analysis
To examine the association between the ESR-α polymorphisms and breast cancer risk, a search of the MEDLINE database (from January 1990 to March 2010), EMBASE, Cochrane, and the US National Library of Medicine's PubMed database (http://www.ncbi.nlm. nih.gov/pubmed) was performed. In addition, various scientific research tools available on the web were used to search relevant references such as Google (http:// scholar.google.com/) and Scirus (http://www.scirus.com/). We focused on the two well-characterized polymorphic variants: PvuII and XbaI. Keywords used in searches included 'estrogen receptor' in combination with the terms 'polymorphism', 'genotype', 'allele', 'breast cancer' or 'risk'.
Papers selected for this meta-analysis included a casecontrol study and complete data. All relevant references that met the inclusive criterion were required to be published as articles or abstracts and to contain original data. Case-only studies, studies without complete data, or studies with inadequate control groups were excluded.
To estimate associations with breast cancer risk, various genotypic models were selected. Both the Peto Mantel-Haenszel fixed-effects model and the DerSimonian Laird random-effects model were used to calculate summary ORs, and both within-and betweenstudy variations were considered (DerSimonian et al., 2007) . A P-value of less than 0.10 was considered statistically significant when comparing trials showing heterogeneity, and random-effects analysis was selected for such trial; in contrast, fixed-effects analysis was used for comparing trials showing homogeneity. Inverted funnel plots were used to examine asymmetry; the ORs were plotted on a logarithmic scale against the inverse of their corresponding standard errors (Oxman et al., 1993) . In the presence of publication bias, the funnel plot was asymmetric, and the data showed remarkable skewness. There may be many reasons for this, most notably that some studies with negative findings are not published. In contrast, the plots were symmetric when bias was absent.
Statistical analysis
Tests for Hardy-Weinberg equilibrium were performed separately for each SNP among case and control subjects. An independent samples t-test was used to determine differences according to age, and the chi-square or Fisher's exact test was performed to calculate the clinical parametric distributions. Unconditional logistic regression analysis models were used to evaluate the relationships between different genotypes and disease risk [odds ratios (OR), 95% confidence intervals (95% CI)] adjusted by age. Linkage disequilibrium and haplotypes were analyzed with the SHEsis software (Shi et al., 2005; Li et al., 2009 ).
All of the statistical analyses were performed in the Statistical Package for Social Sciences (SPSS, version Table 1 shows the demographic and clinical characteristics of the subjects (542 breast cancer patients and 1,016 non-cancer controls). No significant differences in age, smoking status, or alcohol intake were observed between cases and controls. In the present study, two polymorphisms, PvuII and XbaI, located at the 5' end of ESR-α gene were evaluated; each SNP was in HardyWeinberg equilibrium, as shown in Table 2 . Statistical analysis revealed a significant difference in the frequency of the XbaI genotype (P = 0.044), while the PvuII polymorphism did not show any significant differences. Compared to data for the XbaI 'AA', subjects with the 'GG' genotypes were associated with a decreased risk, assessed by chi-square statistics (OR = 0.59, 95% CI = 0.35-0.99, P = 0.042, table not shown). After adjustment for age, the OR value was 0.80 (95% CI = 0.64-1.02, P = 0.069). The XbaI 'G' allelic frequency occurred at 18.5% in cancer patients, which was significantly lower than that observed for controls (22.3%), indicating a decreased disease risk associated with this allele (OR = 0.80, 95% CI: 0.66-0.97, P = 0.022). In addition, the associations of the XbaI or PvuII polymorphisms with breast cancer risk according to different clinical stages (lymph node status), expression of estrogen receptor, or stratified by the average age of 50 years were also evaluated, but no significant differences were observed (Table not shown) . In this report, statistical significance of linkage disequilibrium was detected among these two polymorphisms, and the P value was 6.7×10
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-16 (D' = 0.926, r 2 = 0.417). Haplotypes with the two-loci of ESR-α gene polymorphisms were analyzed with the SHEsis software. The frequency of haplotype 'CG' was 17.7% in cases, significantly lower than that observed for controls (21.2%, P = 0.016), suggesting that 'CG' indicates a decreased disease risk.
Characteristics and qualitative assessment of included studies in the meta-analysis
According to the criteria defined above, 24 published studies relevant to the ESR-α gene and breast cancer risk were reviewed. Ten of these papers were excluded due to insufficient clarity in data presentation, repeated literature, or significant differences present in the study design compared to the other papers identified. The remaining 14 eligible case-control studies (listed in Table 3) were included in a meta-analysis to investigate the associations of PvuII and XbaI polymorphisms with breast cancer risk. In 13 of these studies, 10,419 cases and 16,178 controls were analyzed for the PvuII polymorphism, while 11 studies included 8,542 cases and 12,941 controls analyzed for the XbaI polymorphism. Among controls, the frequency of the 'T' allele at the PvuII site ranged from 48.8% in a Utrecht population of the Netherlands to 64.2% in a Zhejiang population of China (Hu et al., 2007) . In contrast, the frequency of the 'A' allele at the XbaI site among controls ranged from 53.9% in a Dutch population to 77.7% in a Chinese population (Onland-Moret et al., 2005; Hu et al., 2007) .
Assessment of Hardy-Weinberg proportion is regarded as an important criterion for evaluating genetic association studies; caution should be exercised when interpreting the studies included in the meta-analysis (Little et al., 2002) . Most of the studies included in this meta-analysis reported genotype frequencies in their control groups that were consistent with Hardy-Weinberg proportions (P > 0.05). Deviations from Hardy-Weinberg proportions in controls were observed only in four studies for XbaI (Little et al., 2002; Cai et al., 2003; Lu et al., 2005; Shen et al., 2006) .
Funnel plotting was performed to evaluate whether publication bias was present in the meta-analysis performed. As shown in Figure 1 , the shape of the funnel plots obtained appears to be symmetrical in models ('C' vs. 'T') but unsymmetrical in model ('G' vs. 'A'). We hypothesized that the publication bias may be the reason for this heterogeneity.
Meta-analysis of the ESR-α polymorphisms and breast cancer risk
A heterogeneity test of potential associations between Table 4 and Figure 2 . Examining the PvuII polymorphism first, only 13 studies to date have investigated the relationship between the PvuII polymorphism and breast cancer risk, and all of these studies were in Hardy-Weinberg equilibrium (Yaich et al., 1992; Cai et al., 2003; Shin et al., 2003; Wedren et al., 2004; Lu et al., 2005; Onland-Moret et al., 2005; Shen et al., 2006; Hu et., 2007; Kjaergaard et al., 2007; Gonzalez-Mancha et al., 2008; Gonzalez-Zuloeta et al., 2008; Dunning et al., 2009) . Except for the model ('CC' vs. 'CT+TT', P = 0.008), there was little evidence of statistical heterogeneity. Individuals carrying the 'C' allele (OR = 0.96; 95% CI = 0.92-0.99, P = 0.03; P = 0.19 for heterogeneity, I 2 = 24.7%) were associated with a significant decrease in breast cancer diagnosis compared to patients carrying the 'T' allele ( Figure 2 ). In addition, the model ('CC' vs. 'TT') showed a significant association with breast cancer risk, with the associated ORs being 0.91 (95% CI = 0.84-0.98, P = 0.01; P = 0.19 for heterogeneity, I 2 = 25.5%). Compared to the 'TT' genotype, subgroup analysis revealed that genotype 'CC' was associated with a 0.80-fold risk of breast cancer risk in Asians (P = 0.01, fixed effects) but not in Euro-Americans (P = 0.11, random effects, Table 4 ). A total of 11 studies were included in the meta-analysis performed to examine the associations between the XbaI polymorphism and breast cancer risk; four studies of these were not consistent with Hardy-Weinberg proportions (Cai et al., 2003; Shin et al., 2003; Wedren et al., 2004; Lu et al., 2005; Onland-Moret et al., 2005; Shen et al., 2006; Hu et., 2007; Gonzalez-Zuloeta et al., 2008; Dunning et al., 2009 ). Since there is heterogeneity in model ('G' vs. 'A'), random-effects analysis was selected. We observed that individuals carrying the 'G' genotype were associated with a 0.82-fold decreased risk in Asians (95% CI = 0.68-0.98, P = 0.03; P = 0.01 for heterogeneity, I 2 = 65.7%) compared to the data for the 'A' genotype. However, no significant differences were observed between this polymorphism and breast cancer risk in Euro-Americans.
Discussion
Worldwide, the incidence of clinical breast cancer shows a strong dependence on sex, age, race, and geography. For example, the incidence in AfricanAmericans is significantly higher than that in Asians, especially the Chinese population (Smigal et al., 2006; American Cancer Society, 2011) . Recent epidemiological In the present study, we observed that the XbaI 'G' allele was associated with an almost 0.80-fold decreased risk for developing breast cancer compared to patients carrying the 'A' allele in a Chinese population. Results from the meta-analysis with 11 studies included 8,542 cases and 12,941 controls, it showed that the XbaI 'G' allele was associated with a 0.82-fold decreased risk in Asians. However, no significant association was observed between the XbaI 'G' allele and breast cancer risk in EuroAmericans. Although no significant association with breast cancer risk was observed in our study population, the PvuII polymorphism was closely related to breast cancer risk in Asians. The meta-analysis showed that the PvuII 'CC' genotype was linked to a 0.80-fold decreased risk of breast cancer. However, we also did not observed any association between the PvuII polymorphism and breast cancer risk in Euro-Americans. The significant difference between the PvuII or XbaI polymorphisms and breast cancer risk in Asians but not in Euro-Americans, suggests that race, geographical location, and lifestyle may be involved in carcinogenesis.
Although a single genotype or allele may influence the occurrence and development of disease, haplotype might play a more important role considering the strong linkage disequilibrium between these two polymorphisms. We analyzed haplotypes with two-locus (PvuII and XbaI) of ESR-α gene polymorphisms using the SHEsis software and found that the haplotype 'CG' indicates a decreased risk of breast cancer in our study population. Our result supports the conclusion that the PvuII 'C' or XbaI 'G' allele is associated with a decreased risk of breast cancer. At present, few studies have investigated association of this haplotype and the risk of breast cancer. Thus, this finding needs to be further confirmed.
To make a comprehensive and deep analysis of the underlying reason, we evaluated the genotype and allelic frequencies of the ESR-α gene in different populations. We found that the allelic frequency of PvuII 'C' in Asian populations (38.4%, in control) was significantly lower than that observed for Euro-Americans (45.9%, Figure  3A) . The allelic frequency of the XbaI 'G' allele in Asians was 25.4% (in control), significantly lower than that found in Euro-Americans (37.6%, Figure 3B ). Interestingly, we found the lower frequencies of the PvuII 'C' or XbaI 'G' allele occurred mainly in Asians, which was consistent with the lower incidence of breast cancer in these regions (Smigal et al., 2006) . The higher allelic frequencies occurred in Euro-Americans with higher cancer incidence. We hypothesized that the allelic distribution of the PvuII and XbaI may be an important factor resulting in the difference of breast cancer incidence in different regions of the world.
However, the reasons and the underlying molecular mechanisms that the ESR-α gene polymorphisms influence the occurrence of breast cancer remain unknown.
The PvuII and XbaI polymorphic variants are located on the untranslated intron 1 and do not seem to alter the amino acid sequence. However, evidence from several studies shows that the PvuII and XbaI polymorphisms may affect the receptor function through differential splicing of mRNA (Dotzlaw et al., 1992; Fuqua et al., 1992) or alteration of transcriptional elements within introns (Roodi et al., 1995) . A study by Herrington and colleagues (Herrington et al., 2002) found suggests that the PvuII 'C' allele, a potential binding site for myb transcription factors, had a higher transcription of the ESR-α gene compared to the 'T' allele. Additionally, a significant interaction between levels of estradiol (E2) and the PvuII genotype were observed by Onland-Moret et al. (2005) , who reported that women with Low E2 levels and the 'C' allele had a decreased risk of breast cancer compared to women with high E2 levels and the 'T' allele. Besides the E2 levels, the PvuII 'C' allele was also associated with decreased levels of androstenedione (Weiderpass et al., 2000) . Based on these observations, we believe that the ESR-α gene polymorphisms may indirectly influence the binding activity to the hormone response element on the target gene by regulating gene expression or receptor function, and then influence the transcriptional regulation of it's downstream genes including TP53 (Rasti et al., 2012) , causing the origination of the breast cancer.
In summary, the present study indicates that the ESR-α gene polymorphisms may be associated with breast cancer risk. These associations may largely depend on population characteristics and geographic location. Thus, these results help provide laboratory basis for molecular epidemiological studies of breast cancer and a better understanding of the geographic and ethnic differences associated with disease incidence and mortality.
